[阿根廷关于偏头痛患者使用单克隆抗体的共识指南]
[Argentinean consensus guidelines on the use of monoclonal antibodies in patients with migraine].
作者信息
Doctorovich E D, Martín-Bertuzzi F, Goicochea M T, Miranda S, Figuerola M L, Schubaroff P A, Buonanotte F, Rocchi V, Rua I, Bruera O C, Giglio J, De Paz J J, Pelli-Noble R, Arago L, Burgos M, Ayala L S, Davidow L, Bonamico L
机构信息
Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
Instituto de Investigaciones Neurológicas Dr. Raúl Carrea (FLENI), Buenos Aires, Argentina.
出版信息
Rev Neurol. 2020 Feb 16;70(4):149-158. doi: 10.33588/rn.7004.2019399.
INTRODUCTION
Migraine is a very prevalent disorder that is estimated to affect about 15% of adult subjects. Recently, the efficacy and safety of monoclonal antibodies that act on the calcitonin gene-related peptide pathway (MA-CGRP) has been evaluated in migraine. Several groups around the world have developed consensus guidelines about the use of monoclonal antibodies, however, in some regions is difficult to extrapolate the recommendations.
AIM
To provide recommendations for the use of MA-CGRP in migraine in Argentina.
DEVELOPMENT
A group of neurology experts from Argentina, by using the online surveys methodology as well as face to face meetings developed the intended consensus for the use of MA-CGRP in migraine in Argentina. Recommendations were established based on published evidence and the expert opinion. Recommendations focused on how, when, treatment duration and patients follow up.
CONCLUSION
The recommendations of this consensus guidelines attempt to optimize the use of MA-CGRP in migraine in Argentina.
引言
偏头痛是一种非常常见的疾病，据估计约有15%的成年患者受其影响。最近，作用于降钙素基因相关肽途径的单克隆抗体（MA-CGRP）在偏头痛治疗中的疗效和安全性已得到评估。世界各地的几个小组已经制定了关于使用单克隆抗体的共识指南，然而，在一些地区很难推断这些建议。
目的
为阿根廷偏头痛患者使用MA-CGRP提供建议。
制定
一组来自阿根廷的神经学专家通过在线调查方法以及面对面会议，就阿根廷偏头痛患者使用MA-CGRP达成了预期的共识。建议是基于已发表的证据和专家意见制定的。建议集中在如何使用、何时使用、治疗持续时间和患者随访方面。
结论
本共识指南的建议旨在优化阿根廷偏头痛患者对MA-CGRP的使用。
Zotero 插件